The role of modern antithrombotic agents in cardiovascular disease prevention

• Main Authors: O. M. Drapkina, A. V. Klimenkov, V. T. Ivashkin
• Format: Article
• Language: Russian
• Published: «SILICEA-POLIGRAF» LLC 1970-01-01
• Series: Кардиоваскулярная терапия и профилактика
• Subjects: atherosclerosis; atherothrombosis; myocardial infarction; stroke; clopidogrel
• Online Access: https://cardiovascular.elpub.ru/jour/article/view/1677

Atherosclerosis is one of the most urgent problems in modern cardiology. Atherosclerosis instability and coronary heart disease clinical course are based on plaque ulceration, rupture, and atherothrombosis. Atherothrombosis causes 28% of all deaths worldwide. Therefore, usage of medications targeted on atherosclerosis is very important. One of such agents is clopidogrel - thienopyridine, first used in patients with effort angina, stroke (S), or peripheral artery disease, PAD (1997). Clopidogrel demonstrates polyvalent anti-aggregant effects on platelets. Adding clopidogrel to standard therapy improves outcomes in non-ST elevation acute coronary syndrome patients of low, intermediate, and high risk. Relative risk (RR) of death, myocardial infarction (MI), and S decreases by 20%, irrespective of standard treatment. In patients with recent MI, S, or severe PAD, long-term (three-year) clopidogrel treatment reduces RR of MI, S, or cardiovascular death by 8,7%, comparing to aspirin treatment. Clopidogrel prevents ischemic events more effectively (by 26%) than aspirin